Offering Prenatal Screening in the Age of Genomic Medicine

A Practical Guide

Megan Allyse, Umut Aypar, Natasha Bonhomme, Sandra Darilek, Michael Dougherty, Ruth Farrell, Wayne Grody, W Edward Jr. Highsmith, Marsha Michie, Mark Nunes, Laura Otto, Rebecca Pabst, Glenn Palomaki, Cassandra Runke, Richard R Sharp, Brian Skotko, Katie Stoll, Myra J Wick

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aims: In September, 2015, Mayo Clinic convened a panel of national thought leaders on prenatal screening, medical genetics, and obstetrics and gynecology practice. Results: During the 2-day symposium, participants discussed the implications of the shift toward broader prenatal screening using cell-free placental DNA in maternal serum (cfDNA screening). Key topics included challenges around the pace of change in the prenatal screening market, uncertainty around reimbursement, meeting the need for patient counseling, and potential challenges in interpreting and returning cfDNA screening results. Innovation: Here, we describe the challenges discussed and offer clinical recommendations for practices who are working to meet them. Conclusion: As the spread of prenatal genetic screening continues, providers will increasingly need to update their practice to accommodate new screening modalities.

Original languageEnglish (US)
Pages (from-to)755-761
Number of pages7
JournalJournal of Women's Health
Volume26
Issue number7
DOIs
StatePublished - Jul 1 2017

Fingerprint

Prenatal Diagnosis
Medicine
Medical Genetics
Genetic Testing
Gynecology
Obstetrics
Uncertainty
Counseling
Mothers
DNA
Serum

Keywords

  • genetic testing
  • Prenatal care
  • prenatal counseling

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Offering Prenatal Screening in the Age of Genomic Medicine : A Practical Guide. / Allyse, Megan; Aypar, Umut; Bonhomme, Natasha; Darilek, Sandra; Dougherty, Michael; Farrell, Ruth; Grody, Wayne; Highsmith, W Edward Jr.; Michie, Marsha; Nunes, Mark; Otto, Laura; Pabst, Rebecca; Palomaki, Glenn; Runke, Cassandra; Sharp, Richard R; Skotko, Brian; Stoll, Katie; Wick, Myra J.

In: Journal of Women's Health, Vol. 26, No. 7, 01.07.2017, p. 755-761.

Research output: Contribution to journalArticle

Allyse, M, Aypar, U, Bonhomme, N, Darilek, S, Dougherty, M, Farrell, R, Grody, W, Highsmith, WEJ, Michie, M, Nunes, M, Otto, L, Pabst, R, Palomaki, G, Runke, C, Sharp, RR, Skotko, B, Stoll, K & Wick, MJ 2017, 'Offering Prenatal Screening in the Age of Genomic Medicine: A Practical Guide', Journal of Women's Health, vol. 26, no. 7, pp. 755-761. https://doi.org/10.1089/jwh.2016.6098
Allyse, Megan ; Aypar, Umut ; Bonhomme, Natasha ; Darilek, Sandra ; Dougherty, Michael ; Farrell, Ruth ; Grody, Wayne ; Highsmith, W Edward Jr. ; Michie, Marsha ; Nunes, Mark ; Otto, Laura ; Pabst, Rebecca ; Palomaki, Glenn ; Runke, Cassandra ; Sharp, Richard R ; Skotko, Brian ; Stoll, Katie ; Wick, Myra J. / Offering Prenatal Screening in the Age of Genomic Medicine : A Practical Guide. In: Journal of Women's Health. 2017 ; Vol. 26, No. 7. pp. 755-761.
@article{3662b101cad74941b918afbc3dfa5011,
title = "Offering Prenatal Screening in the Age of Genomic Medicine: A Practical Guide",
abstract = "Aims: In September, 2015, Mayo Clinic convened a panel of national thought leaders on prenatal screening, medical genetics, and obstetrics and gynecology practice. Results: During the 2-day symposium, participants discussed the implications of the shift toward broader prenatal screening using cell-free placental DNA in maternal serum (cfDNA screening). Key topics included challenges around the pace of change in the prenatal screening market, uncertainty around reimbursement, meeting the need for patient counseling, and potential challenges in interpreting and returning cfDNA screening results. Innovation: Here, we describe the challenges discussed and offer clinical recommendations for practices who are working to meet them. Conclusion: As the spread of prenatal genetic screening continues, providers will increasingly need to update their practice to accommodate new screening modalities.",
keywords = "genetic testing, Prenatal care, prenatal counseling",
author = "Megan Allyse and Umut Aypar and Natasha Bonhomme and Sandra Darilek and Michael Dougherty and Ruth Farrell and Wayne Grody and Highsmith, {W Edward Jr.} and Marsha Michie and Mark Nunes and Laura Otto and Rebecca Pabst and Glenn Palomaki and Cassandra Runke and Sharp, {Richard R} and Brian Skotko and Katie Stoll and Wick, {Myra J}",
year = "2017",
month = "7",
day = "1",
doi = "10.1089/jwh.2016.6098",
language = "English (US)",
volume = "26",
pages = "755--761",
journal = "Journal of women's health (2002)",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Offering Prenatal Screening in the Age of Genomic Medicine

T2 - A Practical Guide

AU - Allyse, Megan

AU - Aypar, Umut

AU - Bonhomme, Natasha

AU - Darilek, Sandra

AU - Dougherty, Michael

AU - Farrell, Ruth

AU - Grody, Wayne

AU - Highsmith, W Edward Jr.

AU - Michie, Marsha

AU - Nunes, Mark

AU - Otto, Laura

AU - Pabst, Rebecca

AU - Palomaki, Glenn

AU - Runke, Cassandra

AU - Sharp, Richard R

AU - Skotko, Brian

AU - Stoll, Katie

AU - Wick, Myra J

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Aims: In September, 2015, Mayo Clinic convened a panel of national thought leaders on prenatal screening, medical genetics, and obstetrics and gynecology practice. Results: During the 2-day symposium, participants discussed the implications of the shift toward broader prenatal screening using cell-free placental DNA in maternal serum (cfDNA screening). Key topics included challenges around the pace of change in the prenatal screening market, uncertainty around reimbursement, meeting the need for patient counseling, and potential challenges in interpreting and returning cfDNA screening results. Innovation: Here, we describe the challenges discussed and offer clinical recommendations for practices who are working to meet them. Conclusion: As the spread of prenatal genetic screening continues, providers will increasingly need to update their practice to accommodate new screening modalities.

AB - Aims: In September, 2015, Mayo Clinic convened a panel of national thought leaders on prenatal screening, medical genetics, and obstetrics and gynecology practice. Results: During the 2-day symposium, participants discussed the implications of the shift toward broader prenatal screening using cell-free placental DNA in maternal serum (cfDNA screening). Key topics included challenges around the pace of change in the prenatal screening market, uncertainty around reimbursement, meeting the need for patient counseling, and potential challenges in interpreting and returning cfDNA screening results. Innovation: Here, we describe the challenges discussed and offer clinical recommendations for practices who are working to meet them. Conclusion: As the spread of prenatal genetic screening continues, providers will increasingly need to update their practice to accommodate new screening modalities.

KW - genetic testing

KW - Prenatal care

KW - prenatal counseling

UR - http://www.scopus.com/inward/record.url?scp=85024391923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024391923&partnerID=8YFLogxK

U2 - 10.1089/jwh.2016.6098

DO - 10.1089/jwh.2016.6098

M3 - Article

VL - 26

SP - 755

EP - 761

JO - Journal of women's health (2002)

JF - Journal of women's health (2002)

SN - 1540-9996

IS - 7

ER -